FDA approves Aerie drug sooner than expected – sales staff to grow

For Aerie Pharmaceuticals (Nasdaq: AERI) – a Duke University spinout that is in the process of building out its research and development team locally – Christmas did indeed come early. Aerie announced Dec. 18 that the U.S. Food and Drug Administration has approved its eye drop Rhopressa for the treatment of glaucoma and hypertension i n the eyes, two months ahead of its scheduled PDUFA date. The company also said it has plans to hire a sprawling field sales force. "We are proud of the work we…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news